Clinical trials: FLT3 Gene Mutation
Leukemia, Myeloid, Acute
Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation
This is a Phase 2, multi-center, open-label study to evaluate the efficacy, safety and pharmacokinetics of quizartinib monotherapy in Japanese subjects with FLT3-ITD positive refractory or relapsed acute myeloid leukemia.
- Trial name
- NCT02984995
- Testing
- Quizartinib
- Where
- 27 sites in Japan
- Volunteers
- 37 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Malignant Neoplasm
Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
This phase II trial studies how well ponatinib hydrochloride works in treating patients with cancer that has spread to other parts of the body (metastatic), has failed previous treatment (refractory), and has one of several…
- Trial name
- NCT02272998
- Testing
- ponatinib hydrochloride, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Sameek Roychowdhury
Refractory AML, Relapsed Adult AML
A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE
Gilteritinib is available in early access in France through Temporary Authorisation of Use (or ATU program) since March 2019. The ATU program reflects a real-life treatment situation and the related clinical data would help to…
- Conditions
- Refractory AML, Relapsed Adult AML, FLT3-TKD Mutation, FLT3-ITD
- Trial name
- ELEGANCE (NCT05193448)
- Where
- 38 sites in France
- Volunteers
- 177 people
- Sponsor
- French Innovative Leukemia Organisation
Leukemia, Myeloid
Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation
The purpose of this study is to determine the response rate of patients with refractory, relapsed or poor risk AML expressing FLT-3 activating mutations, when administered CEP-701 at a dosage of 60 mg 2 times a day.
- Trial name
- NCT00030186
- Testing
- CEP-701 60mg, Cep-701 80mg, Cep-701 40mg
- Volunteers
- 37 people
- Sponsor
- Cephalon
Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
HPB-092 effectively inhibits Fms-like tyrosine kinase 3 (FLT3) mutants with comparable or superior potency to approved FLT3 inhibitors and demonstrates improved selectivity, potentially reducing toxicity.
- Trial name
- NCT07137637
- Testing
- HPB-092 tablet
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hangzhou Polymed Biopharmaceuticals, Inc.
Acute Myeloid Leukemia, FLT3 Gene Mutation
Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia
The goal of this clinical trial is to evaluate the efficacy of gilteritinib as induction therapy in FLT3-positive adult acute myeloid leukemia patients.
- Conditions
- Acute Myeloid Leukemia, FLT3 Gene Mutation, Adult AML, Diagnosis
- Trial name
- NCT06667973
- Testing
- Gilteritinib
- Volunteers
- 80 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
FLT3 Gene Mutation, AML
The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation
The FMS tyrosine kinase 3 (FLT3) gene mutation occurs in 30% of newly diagnosed AML patients, leading to a higher relapse rate and mortality rate.
- Trial name
- FLT3AML-2024 (NCT06561880)
- Testing
- Venetoclax, Cytarabine, Gilteritinib
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China